Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409481 | 0.90 | DGAT1 (0.42) | DGAT1ROCK2PIM1PIM3 | |
| SCHEMBL13409162 | 0.88 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL13409480 | 0.86 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL13408579 | 0.85 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL13408593 | 0.84 | ROCK2 (0.41) | DGAT1ROCK2PIM1PIM3 | |
| SCHEMBL14107598 | 0.83 | MEN1 (0.44) | — | |
| SCHEMBL14107625 | 0.82 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL13409170 | 0.82 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL13409142 | 0.82 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL14107592 | 0.81 | DGAT1 (0.35) | DGAT1ROCK2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | DGAT1 3856/4885SLC6A2 2503/4885ROCK2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.